drugset / Trial / NCT04491643

Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma

NCT04491643

Phase 2 Completed 48 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

To explore the treatment efficacy of megestrol acetate plus rosuvastatin in patients with early endometrial carcinoma (EEC) seeking for conservative treatment.

Timeline

Start
2020-09-01
Primary completion
2023-08-11
Completion
2025-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Megestrol Acetate Other / unclassified 160 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications